(Q36192764)

12 August 2017

1 reference

title

Peginterferon-alpha 2a for the treatment of hepatitis B infection (English)

1 reference

12 August 2017

W Graham E Cooksley

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1373-1380

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1373

10.1517/14656566.6.8.1373

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference